KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Deferred Taxes (2019 - 2025)

Historic Deferred Taxes for AbbVie (ABBV) over the last 7 years, with Q3 2025 value amounting to $193.0 million.

  • AbbVie's Deferred Taxes rose 16967.51% to $193.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$874.0 million, marking a year-over-year increase of 5783.89%. This contributed to the annual value of -$1.4 billion for FY2024, which is 4984.42% up from last year.
  • As of Q3 2025, AbbVie's Deferred Taxes stood at $193.0 million, which was up 16967.51% from -$272.0 million recorded in Q2 2025.
  • AbbVie's 5-year Deferred Taxes high stood at $193.0 million for Q3 2025, and its period low was -$1.4 billion during Q4 2023.
  • Its 5-year average for Deferred Taxes is -$382.8 million, with a median of -$277.0 million in 2024.
  • Per our database at Business Quant, AbbVie's Deferred Taxes tumbled by 172647.06% in 2022 and then surged by 16967.51% in 2025.
  • Over the past 5 years, AbbVie's Deferred Taxes (Quarter) stood at -$745.0 million in 2021, then skyrocketed by 30.74% to -$516.0 million in 2022, then tumbled by 169.57% to -$1.4 billion in 2023, then skyrocketed by 44.86% to -$767.0 million in 2024, then soared by 125.16% to $193.0 million in 2025.
  • Its last three reported values are $193.0 million in Q3 2025, -$272.0 million for Q2 2025, and -$28.0 million during Q1 2025.